Dupilumab (Dupixent®) for eosinophilic oesophagitis. HTA ID: 23047

Assessment Status Rapid Review Complete
HTA ID 23047
Drug Dupilumab
Brand Dupixent®
Indication Dupilumab (Dupixent®) is indicated for the treatment of adults and adolescents 12 years and older, weighing at least 40 kg, with eosinophilic oesophagitis (EoE) who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
Assessment Process
Rapid review commissioned 26/07/2023
Rapid review completed 07/09/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dupilumab for this indication compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.